Logo image of RDHL

REDHILL BIOPHARMA LTD-SP ADR (RDHL) Stock Fundamental Analysis

NASDAQ:RDHL - US7574683014 - ADR

1.36 USD
-0.01 (-0.73%)
Last: 8/26/2025, 6:01:44 PM
Fundamental Rating

1

RDHL gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of RDHL have multiple concerns. While showing a medium growth rate, RDHL is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RDHL had negative earnings in the past year.
RDHL had a negative operating cash flow in the past year.
RDHL had negative earnings in 4 of the past 5 years.
RDHL had a negative operating cash flow in each of the past 5 years.
RDHL Yearly Net Income VS EBIT VS OCF VS FCFRDHL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M -80M -100M

1.2 Ratios

RDHL has a Return On Assets of -45.82%. This is comparable to the rest of the industry: RDHL outperforms 43.01% of its industry peers.
Industry RankSector Rank
ROA -45.82%
ROE N/A
ROIC N/A
ROA(3y)4.28%
ROA(5y)-16.67%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RDHL Yearly ROA, ROE, ROICRDHL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K

1.3 Margins

Looking at the Gross Margin, with a value of 60.31%, RDHL is in the better half of the industry, outperforming 67.88% of the companies in the same industry.
In the last couple of years the Gross Margin of RDHL has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for RDHL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.56%
GM growth 5Y-1.2%
RDHL Yearly Profit, Operating, Gross MarginsRDHL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

0

2. Health

2.1 Basic Checks

RDHL does not have a ROIC to compare to the WACC, probably because it is not profitable.
RDHL has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RDHL has more shares outstanding
Compared to 1 year ago, RDHL has an improved debt to assets ratio.
RDHL Yearly Shares OutstandingRDHL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M
RDHL Yearly Total Debt VS Total AssetsRDHL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

RDHL has an Altman-Z score of -35.02. This is a bad value and indicates that RDHL is not financially healthy and even has some risk of bankruptcy.
RDHL's Altman-Z score of -35.02 is on the low side compared to the rest of the industry. RDHL is outperformed by 87.05% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -35.02
ROIC/WACCN/A
WACC8.2%
RDHL Yearly LT Debt VS Equity VS FCFRDHL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

2.3 Liquidity

RDHL has a Current Ratio of 0.54. This is a bad value and indicates that RDHL is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.54, RDHL is doing worse than 93.26% of the companies in the same industry.
A Quick Ratio of 0.37 indicates that RDHL may have some problems paying its short term obligations.
RDHL has a Quick ratio of 0.37. This is amonst the worse of the industry: RDHL underperforms 93.26% of its industry peers.
Industry RankSector Rank
Current Ratio 0.54
Quick Ratio 0.37
RDHL Yearly Current Assets VS Current LiabilitesRDHL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

RDHL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -100.30%.
The Revenue has grown by 23.17% in the past year. This is a very strong growth!
RDHL shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.04% yearly.
EPS 1Y (TTM)-100.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100.3%
Revenue 1Y (TTM)23.17%
Revenue growth 3Y-54.57%
Revenue growth 5Y5.04%
Sales Q2Q%23.17%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
Based on estimates for the next years, RDHL will show a very strong growth in Revenue. The Revenue will grow by 45.22% on average per year.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year82.69%
Revenue Next 2Y55.97%
Revenue Next 3Y45.22%
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
RDHL Yearly Revenue VS EstimatesRDHL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M
RDHL Yearly EPS VS EstimatesRDHL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 -500 -1K -1.5K -2K -2.5K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RDHL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RDHL Price Earnings VS Forward Price EarningsRDHL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RDHL Per share dataRDHL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RDHL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REDHILL BIOPHARMA LTD-SP ADR

NASDAQ:RDHL (8/26/2025, 6:01:44 PM)

1.36

-0.01 (-0.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)09-16 2024-09-16
Earnings (Next)N/A N/A
Inst Owners4.3%
Inst Owner Change-45.8%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap3.12M
Analysts82.86
Price TargetN/A
Short Float %1860%
Short Ratio0.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.39
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.76
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-4.09
FCFYN/A
OCF(TTM)-4.09
OCFYN/A
SpS3.51
BVpS-2.04
TBVpS-4.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -45.82%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.31%
FCFM N/A
ROA(3y)4.28%
ROA(5y)-16.67%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.56%
GM growth 5Y-1.2%
F-Score3
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.45%
Cap/Sales 0.11%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.54
Quick Ratio 0.37
Altman-Z -35.02
F-Score3
WACC8.2%
ROIC/WACCN/A
Cap/Depr(3y)1.49%
Cap/Depr(5y)123.93%
Cap/Sales(3y)0.2%
Cap/Sales(5y)16.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-100.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100.3%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)23.17%
Revenue growth 3Y-54.57%
Revenue growth 5Y5.04%
Sales Q2Q%23.17%
Revenue Next Year82.69%
Revenue Next 2Y55.97%
Revenue Next 3Y45.22%
Revenue Next 5YN/A
EBIT growth 1Y-215.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y73.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y73.84%
OCF growth 3YN/A
OCF growth 5YN/A